BK Treatment Study

Status:	Completed
Conditions:	Infectious Disease
Therapuetic Areas:	Immunology / Infectious Diseases
Healthy:	No
Age Range:	Any
Updated:	9/23/2012
Start Date:	February 2009
End Date:	September 2012
Contact:	Anil Chandraker, MD
Email:	achandraker@rics.bwh.harvard.edu
Phone:	617-732-7412

Effect of Fluoroquinolones on BK Viremia in the Renal Transplant Recipient, A Multi-Center Study

Our hypothesis is that 30 days of oral levofloxacin (FDA approved antibiotic) in patients
with persistent viremia (BK virus found in blood) will impair progress to BK virus induced
kidney damage by significantly decreasing or eliminating BK virus in the blood.

Inclusion Criteria:

- Living and cadaveric kidney transplant recipients over the age of 18 years with BK
viremia

Exclusion Criteria:

- Female patients of childbearing age who are pregnant or in whom adequate
contraception cannot be maintained.

- Patients with active infections, history of malignancy/Posttransplant
Lymphoproliferative Disease (PTLD) serologic positivity to HIV.

- Patients with evidence of urinary tract obstruction causing allograft dysfunction,
unless corrected by time of enrollment.

- Patients with clinical or morphological evidence of recurrence of primary disease.

- Patients with a history of allergic reaction to quinolone antibiotics.

- Patients with history of prolong QT interval

- Patients with recurrent hypoglycemic episodes

- Patients with history of myasthenia gravis

- Patients taking Thioridazine

We found this trial at

sites

Lahey Clinic Medical Center

Burlington, Massachusetts 01805

from

Burlington, MA